Who makes Ketamine [Ketalar]?

Ketamine [Ketalar] is developed by Medical University of Warsaw.

What development phase is Ketamine [Ketalar] in?

Ketamine [Ketalar] is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Ketamine [Ketalar]

Medical University of Warsaw · FDA-approved active Small molecule Quality 2/100

Ketamine [Ketalar], marketed by the Medical University of Warsaw, is a well-established anesthetic with a key composition patent expiring in 2028. Its primary strength lies in its robust market presence and long-standing use in medical settings. The primary risk is the potential increase in competition following the patent expiry in 2028.

At a glance

Generic name	Ketamine [Ketalar]
Sponsor	Medical University of Warsaw
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Ketamine [Ketalar] CI brief — competitive landscape report
Ketamine [Ketalar] updates RSS · CI watch RSS
Medical University of Warsaw portfolio CI